150 related articles for article (PubMed ID: 38081586)
1. Flexible evaluation of surrogate markers with Bayesian model averaging.
Duan Y; Parast L
Stat Med; 2024 Feb; 43(4):774-792. PubMed ID: 38081586
[TBL] [Abstract][Full Text] [Related]
2. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
Parast L; McDermott MM; Tian L
Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
[TBL] [Abstract][Full Text] [Related]
3. Evaluating multiple surrogate markers with censored data.
Parast L; Cai T; Tian L
Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
[TBL] [Abstract][Full Text] [Related]
4. Robust methods to correct for measurement error when evaluating a surrogate marker.
Parast L; Garcia TP; Prentice RL; Carroll RJ
Biometrics; 2022 Mar; 78(1):9-23. PubMed ID: 33021738
[TBL] [Abstract][Full Text] [Related]
5. Using a surrogate marker for early testing of a treatment effect.
Parast L; Cai T; Tian L
Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of longitudinal surrogate markers.
Agniel D; Parast L
Biometrics; 2021 Jun; 77(2):477-489. PubMed ID: 32506496
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
Wang X; Cai T; Tian L; Bourgeois F; Parast L
Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
[TBL] [Abstract][Full Text] [Related]
8. Robust approach to combining multiple markers to improve surrogacy.
Wang X; Parast L; Han L; Tian L; Cai T
Biometrics; 2023 Jun; 79(2):788-798. PubMed ID: 35426444
[TBL] [Abstract][Full Text] [Related]
9. Testing for heterogeneity in the utility of a surrogate marker.
Parast L; Cai T; Tian L
Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
[TBL] [Abstract][Full Text] [Related]
10. Evaluating surrogate marker information using censored data.
Parast L; Cai T; Tian L
Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.
Zhou RR; Zhao SD; Parast L
Stat Med; 2022 May; 41(12):2227-2246. PubMed ID: 35189671
[TBL] [Abstract][Full Text] [Related]
12. Accounting for treatment by center interaction in sample size determinations and the use of surrogate outcomes in the pessary for the prevention of preterm birth trial: a simulation study.
Willan AR
Trials; 2016 Jul; 17(1):310. PubMed ID: 27378231
[TBL] [Abstract][Full Text] [Related]
13. Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker.
Wang X; Parast L; Tian LU; Cai T
Biometrika; 2020 Mar; 107(1):107-122. PubMed ID: 32587413
[TBL] [Abstract][Full Text] [Related]
14. Using a surrogate with heterogeneous utility to test for a treatment effect.
Parast L; Cai T; Tian L
Stat Med; 2023 Jan; 42(1):68-88. PubMed ID: 36372072
[TBL] [Abstract][Full Text] [Related]
15. Sample size calculations for ROC studies: parametric robustness and Bayesian nonparametrics.
Cheng D; Branscum AJ; Johnson WO
Stat Med; 2012 Jan; 31(2):131-42. PubMed ID: 22139729
[TBL] [Abstract][Full Text] [Related]
16. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
Cowles MK
Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
[TBL] [Abstract][Full Text] [Related]
17. A rank-based approach to evaluate a surrogate marker in a small sample setting.
Parast L; Cai T; Tian L
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38386359
[TBL] [Abstract][Full Text] [Related]
18. Flexible evaluation of surrogacy in platform studies.
Sachs MC; Gabriel EE; Crippa A; Daniels MJ
Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
[TBL] [Abstract][Full Text] [Related]
19. Doubly robust evaluation of high-dimensional surrogate markers.
Agniel D; Hejblum BP; Thiébaut R; Parast L
Biostatistics; 2023 Oct; 24(4):985-999. PubMed ID: 35791753
[TBL] [Abstract][Full Text] [Related]
20. Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint.
Quan H; Xu Z; Luo J; Paux G; Cho M; Chen X
Pharm Stat; 2023; 22(4):633-649. PubMed ID: 36866697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
